Connect with us

Cannabis News

Is America Trippin’? – Almost 30% of Americans Have Tried Psychedelics at Least Once



american psychedelics

When you talk about psychedelics, it is the belief of some people that psychedelics aren’t popular. Some even go as far as saying they are not cool and trendy. However, a recent poll by YouGov might convince you otherwise. The poll sought to explore how many Americans have tried psychedelic substances at least once and the responses might be surprising to many. Read on as we explore how 28 percent of Americans have tried psychedelic substances at least once.

The poll by YouGov was conducted between July 22 and 25 were 1000 adults were asked to respond to questions on an online survey. These 1000 respondents served as the sample size for the larger population and inquiries were made regarding psychedelics. The results of the survey showed that 28 percent of Americans have used at least one of the seven types of psychedelics being inquired about. The order of the psychedelics in terms of usage is LSD (14%), psilocybin (13%), MDMA (9%), ketamine (6%), DMT (6%), and saliva (5%).

One major takeaway that can be taken from this survey is that the acceptance and popularity of psychedelics are gradually increasing among Americans. This increasing popularity is bound to have a consolidatory effect on the push for legislation and decriminalization. YouGov is also of this opinion as the stated that the change in policy and public opinion on psychedelics shows that the tide may be changing. States in the U.S such as California and Oakland have decriminalized psilocybin which is known as psychedelic mushrooms. Other states are also following in those steps with Colorado voting on whether psilocybin is state-wide by November. Oregon will also be allowing the use of psilocybin for mental health treatments by January 2023 under specific conditions.

A closer analysis of the demography of the respondents gives a good picture of which socioeconomic class the product is gaining more popularity from. Males seemed to dominate the positive responses as 34% of respondents identify as males while 22% percent identified as females. As expected, the youths are heavily represented when we go the way of the age of respondents. Participants aged between 18 to 29 years make up 35% of respondents, 39% are aged between 30 to 44 years and 14% are over 65. 

From the economic class of things, respondents were classified based on family income. The available classes are $50,000 or less, between $50,000 and $100,000, and $100,000 or more. According to this, 42% have a family income of $100,000 or more, 34% have between $50,000 and $100,000, and 23% have a family income of $50,000 or less. This shows that psychedelics are somewhat popular among the upper class. Yet, there is also a good representation of those who earn less. A similar trend also showed in terms of the educational status of those who have tried psychedelics at least once. 42% of the positive respondents have a postgraduate degree, 26% have an undergraduate degree, and 24% have a high school degree or lower.

Geographical location in the U.S is very important when it comes to public view and opinion and the same was shown here. Rural areas had a low percentage of respondents with 19% while those living in the suburbs and cities were represented with 26% and 36% respectively. In terms of region, the responses followed the trend of regions with legal laws for psilocybin. The western region of the United States was represented by 37% of the respondents, 34% from the Northeast, and 23% in unspecified regions of the south.

The final identifier used to classify the demography of the respondents is sociopolitical views. This was classified as either very conservative, conservative, or liberal. The results show that 52% of the respondents were liberal and had all tried at least one psychedelic drug. As expected, most respondents who identified as very conservative have rarely tried psychedelics. The same trend of response was also given by respondents who identified as conservative. 

The responses to psychedelics proved to be very positive for their popularity of psychedelics. However, it was quite stiff in terms of acceptance of the products. This is because the majority of the respondents still opposed the decriminalization of the natural product. LSD and MDMA faced the highest opposition as 53% were strongly against their legalization. Psilocybin was also greatly opposed by respondents as 44% were against decriminalizing it. The reality of this result is that those who have had experience with psychedelics are prone to push for its decriminalization. Likewise, support for legalization is very low among those who have not had prior experience with psychedelics.

The medical argument in favor of psychedelics remains among enthusiasts and reform advocates. Many who have tried the psychedelic substance at least once before are very vocal about its use as a medical treatment. Research into the clinical evidence of psilocybin is still very slow and there is a need for bipartisan support to push. The most talked about now is the use of psychedelics to help veterans to deal with post-traumatic stress disorder (PTSD). Participants in the survey were also asked about their opinion of that research and 54% supported it while 18% opposed it. Sixty-three percent of respondents with postgraduate degrees supported the research along with 49 percent of those without a college degree.

The reality is that there is still a long way to go for the decriminalization of most psychedelics. Cannabis also followed the same route before it gained prominence and was legalized in multiple states. Though the cases seem similar, there are also different in multiple respects. The push for psychedelics has gotten off on good ground based on popularity. Next is information that will be useful to enlighten and educate the public on the usefulness and benefits of the products. Afterward, we can start to look at the good days ahead for psychedelics.   





Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.

Cannabis News

New York to Accept Retail Dispensary Apps August 25




It is finally here: New York’s Office of Cannabis Management (OCM) announced that it will begin accepting applications for the Conditional Adult-Use Retail Dispensary (CAURD) Licenses on August 25, 2022. Applications will be accepted through the OCM’s online portal and the application window will close on September 26, 2022. This is obviously a huge deal and the first step towards legal sales of adult-use cannabis in New York.

As a brief refresher, this is a conditional license that moves forward New York’s stated goal of prioritizing social equity applicants. Even if the non-conditional adult-use licenses follow shortly hereafter, it means a lot that the first sales of cannabis in New York will come from businesses owned by individuals who have suffered from New York’s needless and damaging war on cannabis. The two big ticket items for CAURD applicants:

  • Applicants must have a marijuana-related offense conviction that occurred prior to the MRTA being passed on March 31, 2021, or a parent, legal guardian, child, spouse or dependent with a pre-MRTA marijuana-related offense conviction in the State of New York; and
  • Applicants must have experience owning and operating a qualifying business.

We have all of the critical breakdowns of the CAURD license:

This is a big deal, and for anyone interested in applying for a CAURD license, we strongly recommend contacting an experienced cannabis attorney (including us!).

Stay tuned for future development on New York’s cannabis industry and an update after the Cannabis Control Board’s meeting on Monday, August 15, 2022. We will keep you posted.

Source link

Continue Reading

Cannabis News

I Just Do CBD, Not THC




THC in CBD products


Is it a problem that scientists find THC in over 60% of CBD products they tested?


There is every possibility that when you purchase a CBD product from your local supplements or grocery store, you could be getting a little something more than you bargained for, a new study cautions. According to reports from researchers in the journal Drug and Alcohol Dependence, up to 60% of CBD products examined in the lab also contain tetrahydrocannabinol (THC), the chemical compound in weed that makes one high.


Short for cannabidiol, CBD is the second most predominant active ingredient in the Cannabis Sativa plant, which can also be called marijuana or cannabis. Unlike cannabis which gives a strong intoxicating effect when smoking due to the presence of tetrahydrocannabinol (THC), this isolated compound does not give a high when consumed.




According to Shanna Babalonis, the senior researcher and an assistant professor of behavioral science at the University of Kentucky College of Medicine, a majority of the products contain only trace amounts of THC. Still, those trace amounts are enough to gather in your body, and as a result, you can fail a drug test. She claimed that using a CBD product just randomly bought at a store might put military personnel, professional and amateur sports, and persons involved in legal conflicts like child custody battles in danger without them being none the wiser.


“The Olympics forbid the use of THC. A lot of other sporting organizations forbid it. However, athletes utilize CBD since it aids in their recovery and other aspects of their training, “added Babalonis. Therefore, I believe that one of the most important lessons to be learned from this research is that the general population has to inquire about the presence of THC in CBD products.


CBD or Cannabidiol is a chemical compound in cannabis that does not make you intoxicated. Instead, it has been praised for having a number of possible health benefits.




The senior researcher, Shanna Babalonis, and her associates purchased eighty different CBD products for this investigation from Kentucky shops or online retailers. To precisely ascertain whether each product contained any THC, nine analyses were performed on each one.


In addition, Epidiolex, the sole CBD medicine on the market with approval from the Food and Drug Administration, was put to the test. Epidiolex is a medication that is given to treat epileptic seizures, and the production of the drug is strictly controlled.


The scientists discovered that Epidiolex only comprised 0.022 milligrams of THC per milliliter, which is barely noticeable. So, using that background, we compared all the other CBD products, Babalonis added. We discovered this in the FDA-approved product that underwent quite rigorous controls. They discovered that fifty-two out of the eighty CBD products had some THC in them, and all but five of those had amounts higher than in Epidiolex.


Associate vice president of consumer clinical content development at the Partnership to End Addiction in New York City, Pat Aussem stated that if a person does not have a tolerance for THC, these trace quantities can build in a user’s fat cells over time, may have an effect on them. She wasn’t involved in the research.


According to Babalonis, several of the CBD products had levels of THC that might make some consumers intoxicated, most especially if they had never used marijuana before. Eleven products contained more than one milligram of THC per milliliter, while one product had more than two milligrams per one millimeter. This is of great concern because many older individuals take CBD along with numerous other drugs, and their products may include significant doses of THC, Babalonis added. She could not speak on the reason why so many CBD products contain THC.


In order to find and buy CBD products with CBD content on the packaging that was available for online retail purchase, another researcher,  Bonn-Miller, and his study team searched the internet. More than 42% of the items were under-labeled, meaning they included more CBD than was reported, according to the team’s analysis of 84 products from 31 different companies. Another 26% of the items bought had incorrect labels, which meant they contained less CBD than was claimed. Their result was similar to that of Shanna Babalonis.




Babalonis stated that it is certainly possible to take out all the THC. About 30% of all the products that were tested did not have any THC in them. Babalonis added that the cause of this phenomenon could be poor quality testing and sloppy manufacturing processes, but she suspects that some instances might involve manipulation by the consumer.


Just to be a little bit pessimistic, we could assume that if an individual feels an effect from something, if they experience an impressionistic effect, they might be inclined to think that the product is effective, said Babalonis. On the other hand, if an individual does not necessarily experience any effects from something, they would be inclined to think that the thing does not work.


These outcomes indicate the need for more stringent rules for CBD products, both Aussem and Babalonis stated.


Customers should receive realistic marketing claims, and if they choose to purchase CBD products, they should be informed of all ingredients, according to Aussem. CBD products have been on the rise for a while, marketed for an assortment of ailments without studies to back it and without restriction on quality control, one expert says.


Twenty-one of the examined goods carried the “THC Free” label. The investigation found that five of these had THC levels that could be detected.


When purchasing a drink at the grocery store, Babalonis stated, You would expect to see that there is no alcohol in it when it says there is no alcohol in it. You would not drink it expecting to experience the effects of alcohol or even test positive for alcohol on a Breathalyzer. The same thing applies here.



After reading this article, I would have to tell you to think twice before you purchase a seemingly ordinary over-the-counter CBD product, as research shows there is more to them than meets the eye (literally). Suggestions that will go a long way in dealing with this occurrence are the provision of more stringent rules for the manufacturing of CBD products and a quality testing process acknowledged by the F grade given to them.



thc has more medical properties than CBD


Source link

Continue Reading

Cannabis News

Inflation Finally Comes to Cannabis




inflation in cannabis

1 In 4 Cannabis Retailers Are Raising Prices To Combat Rising Inflation Costs

Inflation is hitting major sectors of the economy, and the cannabis market isn’t left out.


In the following weeks or months, there could be a major shift in the purchase habits of cannabis users all over the country. Inflation is ruining not only summer plans but also regular budgets. Many people are feeling the impacts of high-rising costs, and the majority are beginning to voice their pains because it’s hitting them where it hurts.


So far, cannabis and its derived products are yet to reach a double-digit increase, as seen in food items like chicken and avocados. It wasn’t until recently that the prices began inching upward; in the past, they fell. Between January 2021 and January 2022, it was reported that the costs of cannabis edibles, flowers, and vaping items fell by 11.8%, 16.75%, and 12.40%, respectively.


The predicted rise in cannabis products due to inflation can be linked to various reasons, from insufficient production materials to the apparent disruption in the supply chain distribution. Prices of most things, even necessities, are at their all-time high for four decades. Word on the street is that if your favorite item is yet to increase in price, it’s only a matter of time. The rising cost of packaging materials is at its highest, so no industry would be left out of this.


Cannabis Price Survey

In June, GreenGrowth CPAs conducted a month-long survey in which they questioned operators about the impact of price volatility on their pot business. The poll looked at more than 700 businesses in jurisdictions where cannabis usage is permitted for either medical or recreational purposes. Both small multi-state operations and big ones fall under this category.


In response to growing inflation expenses, 1 in 4 operators said they intended to hike prices in the near or immediate future. More than 50% of the survey participants say that during the past year, the global cannabis economy has deteriorated.


Derek Davis, founder, and CEO of GreenGrowth, noted that the cannabis industry is constantly evolving. He said that his firm took into account many variables affecting the financial performance of cannabis enterprises to give accurate financial statistics, as well as the economic effects of growing inflation expenses. “By polling our clients and cannabis business owners in general, we can gather enough information to have a thorough analysis of how the current economic climate is affecting weed business owners,” Davis continued.


Laying Blames

Volunteers of the GreenGrowth survey suggested that the current inflation plaguing the U.S. cannabis business space can be blamed on the petroleum industry and the Biden Administration.

40% of survey participants blamed the Biden Administration for general inflation problems, 30% blamed residual effects from the Trump Admin, 20% faulted outside influences like the war in Ukraine, and several other participants decried supply chain problems and petroleum companies.


The result of the survey, released on Monday, revealed at least 25% of legal cannabis dispensary operators are on the verge of raising the prices of their stock to battle the rising costs of operations in the immediate future. Compared to 2021 and 2021, 70 percent of a similar study were optimistic about steady improvements in the industry. Today, not so much. Financial operators in the industry now find themselves tackling a number of fresh difficulties and commercial barriers every other day.


During the pandemic, an increase in demand was advantageous for many operators, who leveraged this newfound wealth to implement ambitious growth strategies. Now, minorities perceive a decelerating business climate and are increasing prices to offset growing inflation costs, which has an adverse effect on their profits and operational performance.


GreenGrowth noted that it’s not all bad news. About 70% of operators revealed that they’d try their best to bear the increased costs connected with inflation before raising client prices. According to reports from GreenGrowth, operators that anticipate increased costs may raise prices by as much as 10% for consumers.


Why did it take this long?

The weed industry escaped inflation for a long time. Mainly because there was too much weed in circulation. Weed shops were forced to keep their prices at the same rates to stay above the competition. Raising cannabis prices at such a time would have been more or less a death sentence.


Seattle-based Ganja Goddess general manager, Jason McKee, pointed out that it is very risky to raise prices when customers know they have multiple options. As of the time McKee gave this interview, cannabis stores had begun to see a slight decline in sales. She had mentioned that their store’s sales strategy involved keeping the customer interested in their products and willing to come back.


It is not only retailers that are stuck at the same pricing levels. Growers also compete with fellow growers to supply dispensaries. Like consumers, dispensaries also go for growers with lower prices, despite knowing that production expenses are on the rise.


About GreenGrowth Firm

GreenGrowth is an accounting and advisory firm with Certified Public Accountants (CPAs). Founded in 2016, the company’s objective is to assist budding cannabis firms with business and tax strategies that would keep them in the green. To learn more about the company, you can visit its YouTube Channel, which currently has about 14,000 active subscribers. This channel provides useful business knowledge that would profit operators in the cannabis market.


Bottom Line

The pandemic has left the entire supply chain in a disarray, and transportation is being curtailed everywhere. Long lines and a backlog at the dock make it difficult to import items, which drives up the cost of even the most basic materials—even those used for cannabis cultivation and retail sales.


The cannabis industry is currently feeling the squeeze of inflation on the supply chain. Like Matt Gaboury of House of Cultivar said some months back, everyone will continue a rambling to switch vendors for things like packaging materials, especially the 70 percent that has chosen to bear the incurred costs themselves.


A general price increase is unavoidable in the long run, as the abundance of weed in the market will even out at a point. There’s only so much anyone can do to match inflation.





Source link

Continue Reading


Copyright © 2021 The Art of MaryJane Media